Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
consecutive day dosing of high dose cytarabine consolidation
C · Comparison 대조 / 비교
conventional dosing for acute myeloid leukemia
O · Outcome 결과 / 결론
추출되지 않음
High-dose cytarabine given on days 1, 3, and 5 (HDAC-135) is a mainstay of consolidation treatment for acute myeloid leukemia (AML).
APA
Liu AJ, Batterham E, et al. (2026). Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.. Leukemia & lymphoma, 67(2), 423-435. https://doi.org/10.1080/10428194.2025.2599991
MLA
Liu AJ, et al.. "Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.." Leukemia & lymphoma, vol. 67, no. 2, 2026, pp. 423-435.
PMID
41410640 ↗
Abstract 한글 요약
High-dose cytarabine given on days 1, 3, and 5 (HDAC-135) is a mainstay of consolidation treatment for acute myeloid leukemia (AML). Recent evidence indicates that consecutive daily dosing (HDAC-123) accelerates hematologic recovery and reduces hospitalization duration without compromising survival. However, the impact of HDAC-123 on infection outcomes is unclear. We performed a retrospective analysis of 73 AML patients undergoing HDAC consolidation, including 24 (33%) patients aged ≥60 years. Thirty-six patients received HDAC-135, and 37 received HDAC-123. HDAC-123 was associated with a shorter duration of neutropenia (8 versus 10 days, < .001), fewer neutropenic infections (58% versus 79%, = .02), and a reduced cumulative number of bacteremia episodes per patient (1.54 versus 3.30, = .03), particularly from Gram-negative pathogens (1.22 versus 3.15, = .003) compared to HDAC-135. HDAC-123 was well tolerated across all ages and demonstrated improvements in infection-related complications, supporting its use as a safe and effective consolidation strategy in AML.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Leukemia
- Myeloid
- Acute
- Male
- Female
- Middle Aged
- Cytarabine
- Aged
- Retrospective Studies
- Consolidation Chemotherapy
- Adult
- Antimetabolites
- Antineoplastic
- Drug Administration Schedule
- Treatment Outcome
- 80 and over
- Antineoplastic Combined Chemotherapy Protocols
- Young Adult
- Infections
- Acute myeloid leukemia
- consolidation chemotherapy
- high dose cytarabine
- infection
… 외 1개
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.